Tempest Therapeutics (TPST) Stock Analysis: AI Score & Alternative Data
Alt-data signals are cooling for Tempest Therapeutics
Is Tempest Therapeutics a buy right now? The alternative data says hold. This TPST stock analysis is built on the 25+ alternative data signals AltIndex tracks on Tempest Therapeutics every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 46/100: a Hold. The stock trades at $0.95 with a $17M market cap.
The soft spots over the past 90 days: web traffic down 29.4% to 2K monthly visits, and headcount (according to LinkedIn) down 7.7% to 12 employees. The rest of the signal set is holding steady, which keeps TPST at a hold rather than a sell.
TPST’s broader alt-data profile also covers X followers (389), and sentiment (100/100). Every signal links to its own page with full history, the TPST technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on TPST is just below.
Tempest Therapeutics AI Stock Analysis
Tempest Therapeutics is a clinical-stage oncology company focusing on the development of novel cancer therapeutics. The company's strategy emphasizes innovative approaches to tackling difficult-to-treat cancers by targeting critical aspects of cancer biology.
Analysis generated July 1, 2026.
Recent Tempest Therapeutics Stock Alerts
|
Tempest Therapeutics | July 16 Price is down by -6.5% in the last 24h. |
|
Tempest Therapeutics | July 15 Price is up by 6.1% in the last 24h. |
|
Tempest Therapeutics | July 13 Price is up by 6.4% in the last 24h. |
|
Tempest Therapeutics | July 7 Price is down by -9.9% in the last 24h. |
Tempest Therapeutics Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 2K | 29.4% | |
| Job Posts | 0 | N/A | |
| LinkedIn Employees | 12 | 7.7% | |
| Sentiment | 100 | 0% | |
| Reddit Mentions | 0 | N/A | |
| X Mentions | 11 | 0% | |
| Stocktwits Mentions | 53 | 36.9% | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 13K | 1.7% | |
| 4chan Mentions | 0 | N/A | |
| X Followers | 389 | 1.0% |
About Tempest Therapeutics (TPST)
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors.
| Price | $0.95 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $17M |
| Year Range | $1 – $12 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Tempest Therapeutics News
View more →
Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of DirectorsJune 4 - GlobeNewswire |
|
Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross ProceedsMay 29 - GlobeNewswire |
|
Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026March 11 - GlobeNewswire |
|
 |
Tempest Therapeutics just upgraded at H.C. Wainwright, here's whyJanuary 22 - Thefly.com |
Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026July 15 - GlobeNewswire |
Tempest Therapeutics Earnings & Financial Performance
View all earnings →Tempest Therapeutics Insider Trading Activity
View all →| Angel Matthew filed to sell 231,482 shares at $0.0. Mar 24 '26 |
| Angel Matthew filed to sell 231,482 shares at $0.0. Mar 24 '26 |
| Versant Ventures IV, LLC filed to sell 209,941 shares at $0.0. Aug 12 '24 |
| Versant Ventures IV, LLC filed to sell 597,940 shares at $0.0. Aug 8 '24 |
| Brady Stephen R filed to sell 46,376 shares at $0.0. Jul 3 '24 |
Tempest Therapeutics Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to Tempest Therapeutics
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
SeaStar Medical HoldingICU |
$4.11 2.6% | $17M | 63 |
 |
Sensei BiotherapeuticsSNSE |
$13.85 6.5% | $17M | 64 |
 |
Werewolf TherapeuticsHOWL |
$0.36 1.9% | $18M | 39 |
 |
Vyome HoldingsHIND |
$2.15 1.8% | $16M | 50 |
 |
Allarity TherapeuticsALLR |
$1.20 2.6% | $18M | 48 |
Explore Tempest Therapeutics Data
Frequently Asked Questions: Tempest Therapeutics (TPST)
Tempest Therapeutics has an AltIndex AI Score of 46/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
46/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Tempest Therapeutics (TPST) stock is $0.95 with a market cap of $17M.
As of today, Tempest Therapeutics’s PE (Price to Earnings) ratio is —.
View the latest Tempest Therapeutics insider transactions to see recent buying and selling activity by company executives and directors.
Check the Tempest Therapeutics congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The TPST stock price chart above shows Tempest Therapeutics’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Tempest Therapeutics technical analysis for RSI, moving averages, and more.
See the stocks similar to Tempest Therapeutics section on this page for companies in the same industry ranked by market cap and AI Score.
